Hair Relaxer Lawsuit 2026 | Cancer Claims, Settlements & Legal Updates

The hair relaxer lawsuit litigation has become one of the largest and most closely watched mass torts in the United States. Women across the country have filed claims alleging that long-term use of chemical hair relaxers caused serious health problems, including uterine, ovarian, and endometrial cancers. These lawsuits primarily target major cosmetic manufacturers such as L’Oréal, Strength of Nature, and Revlon, accusing them of failing to warn consumers about the potential risks linked to the endocrine-disrupting chemicals found in their products.

As of 2026, thousands of cases have been consolidated in a federal multidistrict litigation (MDL) in Chicago under Judge Mary Rowland. Alongside the MDL, several state courts are also seeing active filings and early trial preparations. Settlement discussions are underway, expert discovery is progressing, and key rulings continue to shape the future of these claims.

This page provides a detailed overview of the ongoing hair relaxer lawsuits — including the latest legal updates, major court decisions, settlement progress, and what plaintiffs can expect as the litigation moves toward bellwether trials and potential resolutions.

What the Hair Relaxer Lawsuit Is About?

The Hair Relaxer Lawsuit centers on claims that chemical hair straightening products caused serious health issues, including uterine, ovarian, and breast cancers. Plaintiffs allege that manufacturers like L’Oréal, Revlon, and Strength of Nature failed to warn consumers about the risks linked to toxic ingredients such as phthalates and formaldehyde-releasing agents.

These chemicals are known endocrine disruptors that can interfere with hormone regulation, leading to reproductive system damage. The lawsuits claim companies knew or should have known about these dangers but continued marketing the products as safe for regular use, especially targeting women of color.

The litigation aims to hold these corporations accountable for negligence, product liability, and deceptive marketing while seeking compensation for victims’ medical costs, pain, and suffering.

Timeline of the Hair Relaxer Litigation

The following timeline highlights key developments in both the federal multidistrict litigation (MDL) and related state court cases, illustrating how the hair relaxer lawsuits have evolved across different jurisdictions since their consolidation.

September 29, 2025 – Court Removes Plaintiffs Failing to Meet MDL Requirements

The presiding judge dismissed several plaintiffs from the Hair Relaxer MDL who failed to comply with documentation and filing deadlines. This move aims to streamline proceedings and ensure that only valid, fully supported claims remain in the active litigation.

September 18, 2025 – Judge Orders Release of Contested Namaste Communications

On September 18, 2025, the court ordered the disclosure of internal emails from Namaste Laboratories, a key defendant in the Hair Relaxer lawsuit. These documents are expected to shed light on what the company knew about potential health risks tied to its chemical hair straightening products.

September 17, 2025 – Court Sets New Discovery Deadlines and Announces Status Conference

The court established new discovery deadlines for the Hair Relaxer MDL and scheduled an upcoming status conference. The goal is to assess progress, resolve pending disputes, and ensure both sides remain on track for pretrial preparations.

September 11, 2025 – Revised Court Order Establishes Fresh Expert Report Timelines

On September 11, 2025, the judge issued an updated order outlining new deadlines for expert witness reports. This adjustment gives both plaintiffs and defendants additional time to complete expert analyses crucial to proving or contesting the alleged health risks of hair relaxer products.

September 5, 2025 – Sally Beauty Files Lawsuit Against Insurer Over Legal Defense Cost

Sally Beauty initiated a lawsuit against its insurance provider, claiming refusal to cover mounting defense expenses tied to ongoing hair relaxer litigation. The dispute highlights growing tensions between beauty retailers and insurers over liability coverage for product-related lawsuits.

September 4, 2025 – Discovery Challenges and Deposition Delays Involving Avlon Emerge

The court addressed ongoing conflicts with Avlon Industries regarding deposition scheduling and discovery production. These disputes have slowed evidence gathering, prompting the judge to remind all parties of their obligations to cooperate and maintain the MDL’s progress.

September 1, 2025 – Court Announces “Science Day” to Review Expert Medical Findings

The court scheduled a Science Day to allow experts to present medical and toxicological evidence regarding chemical exposure from hair relaxers. The session aims to educate the court on scientific links between product ingredients and alleged cancer and hormonal health risks.

August 23, 2025 – Several Plaintiffs Dismissed for Missing Filing Deadlines

Several plaintiffs were removed from the Hair Relaxer MDL after failing to meet court-imposed filing deadlines. The judge emphasized that timely submissions are essential for maintaining fairness and efficiency in the proceedings as the litigation continues to grow in size and complexity.

August 17, 2025 – New Connecticut Plaintiff Joins the Hair Relaxer MDL

A Connecticut resident joined the expanding Hair Relaxer MDL, adding to the growing list of nationwide plaintiffs. The case highlights increasing recognition of the potential link between chemical hair relaxers and cancers such as uterine and ovarian, reinforcing the lawsuit’s national reach.

August 3, 2025 – Ongoing Growth in Hair Relaxer Litigation Numbers

The Hair Relaxer MDL continued its steady rise in case numbers through August 2025. The increase in filings shows mounting public awareness and legal action against manufacturers accused of failing to warn consumers about the cancer risks associated with prolonged hair relaxer use.

July 22, 2025 – Settlement Progress Slows Despite Discovery Momentum

Although discovery efforts in the Hair Relaxer MDL continued to move forward with steady progress, settlement discussions appeared to have slowed. Both plaintiffs and defendants are focusing on building stronger scientific evidence before entering serious negotiations on compensation and liability terms.

June 23, 2025 – Pennsylvania Court Consolidates Hair Relaxer Lawsuits

A Pennsylvania court ordered the consolidation of multiple state-level Hair Relaxer lawsuits to streamline pretrial proceedings. This move aims to reduce duplicative efforts, improve efficiency, and ensure consistent rulings as more plaintiffs across the country file similar product liability and negligence claims.

June 22, 2025 – Georgia Court Considers Time Limits on Long-Term Exposure Claims

A Georgia court reviewed potential time-bar issues concerning plaintiffs who used chemical hair relaxers decades ago. The debate centers on whether the statute of limitations should begin from the time of diagnosis, given the delayed discovery of cancer links to these products.

June 20, 2025 – Court Prepares for First Hair Relaxer Bellwether Trials

The Hair Relaxer Lawsuit MDL reached a crucial stage as preparations began for the initial bellwether trials. Judge Mary M. Rowland’s case management order laid out the framework for selecting representative cases that will go before juries, offering an early test of how evidence and expert testimony may influence future settlements and verdicts.

For many plaintiffs, this moment marks tangible progress in holding manufacturers accountable for alleged links between chemical hair relaxers and reproductive cancers such as uterine, ovarian, and endometrial cancers. The court’s structured timeline ensures that discovery, expert reviews, and motions move forward efficiently over the next two years.

Key Timeline for Bellwether Preparation

Key Date	Event Description
October 31, 2025	Plaintiffs disclose expert witnesses, including medical and scientific professionals prepared to testify on the cancer risks of chemical relaxers.
December 1, 2025	Defense presents its expert reports, challenging the claimed link between hair relaxer exposure and reproductive cancers.
December 15, 2025	Plaintiffs submit rebuttals, strengthening their scientific evidence and countering the defense’s arguments.
March 2, 2026	All expert discovery is completed, with depositions finalized and positions set for court evaluation.
April 1, 2026	Daubert motions are filed to determine which expert testimonies meet admissibility standards under federal law.
May 1, 2026	Each side files responses defending the credibility of their expert witnesses.
May 15, 2026	Final replies are submitted, paving the way for the judge’s rulings on expert evidence and setting the tone for upcoming trials.

June 15, 2025 – Professional Stylists’ Exposure Cases Gain Legal Weight

Recent developments highlight growing attention toward salon professionals regularly exposed to hair relaxer chemicals. Many stylists allege long-term contact caused hormonal and reproductive health problems. The court has begun treating these occupational exposure claims as a significant part of the litigation, expanding beyond individual consumer use. Legal teams are now gathering evidence to demonstrate that daily professional exposure carries a higher cumulative risk, strengthening these plaintiffs’ positions for future settlements and trial consideration.

June 2, 2025 – Philadelphia Hair Relaxer Cases Move Ahead in State Court

Hair relaxer lawsuits filed in Pennsylvania’s state courts are advancing alongside the federal MDL. The Philadelphia Court of Common Pleas has begun coordinating its growing docket of cases to align with national discovery progress. This ensures consistent handling of expert testimony and scientific evidence across jurisdictions. Plaintiffs in these state cases echo the same core allegations—failure to warn, negligence, and product defect—while attorneys anticipate potential bellwether-style trials at the state level later in the litigation timeline.

April 30, 2025 – Settlement Negotiator Appointed to Facilitate Talks

The court has appointed an experienced settlement negotiator to oversee discussions between plaintiffs and the defendants in the Hair Relaxer Lawsuit. This move signals a stronger push toward potential resolution as both sides prepare for bellwether trials. The negotiator’s role is to bridge differences, explore frameworks for compensation, and identify categories of eligible claims. While no settlement offers have been finalized, this appointment marks a significant step toward structured negotiations that could determine future payout ranges.

February 11, 2025 – Settlement Discussions Begin to Take Shape

Early settlement talks are now underway in the Hair Relaxer multidistrict litigation. Plaintiffs’ attorneys and defense counsel have begun outlining the scope of potential compensation models, considering medical evidence, exposure levels, and cancer types. Although still preliminary, these discussions indicate openness to resolving a portion of the thousands of pending claims outside of trial. Legal observers suggest that progress at this stage could influence the tone of future bellwether trials and overall negotiation momentum throughout 2025.

February 2, 2025 – Judge Outlines Bellwether Trial Schedule for MDL

Judge Mary M. Rowland has released an updated and comprehensive timeline for the upcoming bellwether trials in the Hair Relaxer multidistrict litigation (MDL). The order sets out firm milestones that will shape how the first test cases move forward, determining which lawsuits will be tried first and when expert evidence will be heard.

The outlined schedule reflects the court’s intent to balance efficiency with fairness while ensuring both sides have ample opportunity to complete discovery. These bellwether cases will help gauge jury reactions and guide potential settlements in the broader litigation involving thousands of women alleging that chemical hair relaxers caused reproductive cancers.

Although the first MDL trial is not expected before 2027, related state court trials may begin earlier. If those state verdicts result in major awards, they could pressure defendants such as L’Oréal and other cosmetic companies to reach national settlements sooner.

Hair Relaxer MDL Bellwether Trial Schedule

Date	Event
April 30, 2025	Both parties must identify and exchange 20 Initial Bellwether Discovery Cases.
May 9, 2025	Joint status reports due outlining selected discovery cases.
June 9, 2025	Defendants file Answers and Affirmative Defenses for the Initial Bellwether Cases.
September 30, 2025	Completion of oral fact discovery across the MDL.
October 31, 2025	Plaintiffs submit general causation expert reports supporting their cancer link claims.
December 1, 2025	Defense teams submit their own expert reports challenging causation claims.
February 16, 2026	End of case-specific discovery and submission of position papers for trial case selection.
March 2, 2026	Close of general causation expert discovery and selection of Bellwether Trial Cases.
April 1, 2026	Filing deadline for Daubert motions on general causation experts.
May 1, 2026	Final case-specific discovery completed for Bellwether Trials.
June 30, 2026	Plaintiffs disclose all case-specific and additional expert reports.
August 3, 2026	Defendants file their corresponding expert reports.
October 16, 2026	Close of all remaining expert discovery.
November 16, 2026	Filing deadline for summary judgment and non-causation Daubert motions.
January 6, 2027	Final replies for summary judgment motions due.

Key Takeaways from the Court’s Order

• Expanded Bellwether Pool: The judge increased the number of discovery cases from 16 to 40 to ensure broader representation. Up to 12 of these will advance to trial.
• Eligibility Requirements: Only plaintiffs with uterine, endometrial, or ovarian cancer who filed and served short-form complaints by February 1, 2024, qualify for bellwether selection. Around 5,200 cases meet this standard.
• Selection Process: Both sides will choose 20 cases each, with no extensions beyond the April 30, 2025, deadline.
• Parallel Discovery: The court allows general and case-specific expert discovery to proceed simultaneously to maintain progress.
• Case Substitution Rule: If any discovery case settles before trial selection, plaintiffs may replace it with another eligible case without court approval.

This order demonstrates the court’s determination to move the MDL toward trial readiness while ensuring a fair and balanced review of the scientific and factual evidence central to the Hair Relaxer litigation.

December 4, 2024 – MDL Committee Establishes Common Benefit Fee Structure

The leadership committee overseeing the Hair Relaxer multidistrict litigation (MDL) finalized a plan for a common benefit fund, ensuring that all plaintiffs’ attorneys contributing to shared discovery, expert research, and trial preparation are fairly compensated. This fee structure applies to both federal and state cases that benefit from MDL efforts.

The order outlines a percentage deduction from future settlements or verdicts to fund coordinated work such as expert development, document review, and deposition management. The system is designed to promote collaboration and prevent duplicative efforts while maintaining fairness for all involved firms.

This development marks a critical administrative step toward efficiently managing thousands of claims and ensuring that resources are appropriately distributed when settlements begin.

November 5, 2024 – Uterine Fibroid Lawsuits Regain Focus and Momentum

As scientific attention expands beyond uterine and ovarian cancer, uterine fibroid-related lawsuits are gaining renewed prominence within the Hair Relaxer MDL. Recent medical studies and expert analyses suggest that long-term exposure to certain chemical relaxers may contribute to non-cancerous reproductive issues such as fibroids and hormonal disruptions.

Plaintiffs’ attorneys are now working to highlight these injuries in discovery, seeking to ensure that compensation frameworks reflect both cancer and non-cancer harms. The court’s willingness to consider these additional injury categories could expand the MDL’s scope and lead to a broader, more inclusive settlement structure in the future.

This renewed focus underscores the evolving nature of the litigation as more evidence links chemical hair straighteners to a spectrum of reproductive health conditions.

October 24, 2024 – Overview of Ongoing Hair Relaxer Cases in State Courts

While much of the national focus remains on the federal Hair Relaxer MDL, several state court lawsuits are developing on their own tracks across the U.S. and internationally, with many showing steady progress toward resolution or trial scheduling.

• Cook County, Illinois: Fifty-seven hair relaxer lawsuits have been filed, with forty-four already consolidated before Judge Patrick T. Stanton for coordinated motion practice and discovery. Briefing on dismissal motions for four bellwether cases is complete, and rulings are pending. Discovery remains paused until these decisions are issued. Five cases could head to trial by late 2025 or early 2026, while thirteen others await consolidation following an August 28 hearing.
• Georgia: Twenty cases have been grouped in Chatham County under Judge Derek J. White, though proceedings are temporarily stayed due to an appeal in Burroughs v. L’Oréal USA, Inc., which centers on a statute of repose issue. Another seven cases are active in DeKalb County, with consolidation requests before Judge Alvin T. Wong.
• New York: Two cases in New York County are awaiting rulings on motions to dismiss.
• Pennsylvania: Six cases are ongoing in Philadelphia’s Court of Common Pleas, where plaintiffs and defendants are briefing and pleading challenges. The Pennsylvania docket is expected to grow substantially as more claims are filed and consolidated.
• Canada: Two class action lawsuits have been initiated, but neither has yet advanced to a class certification stage.

Read about the Camp Lejeune Water Lawsuit Updates

Health Risks & Injuries Linked to Hair Relaxer Products

Studies and ongoing litigation have linked long-term use of chemical hair relaxer products to severe health problems, primarily affecting the reproductive system. The most significant risks involve uterine cancer, ovarian cancer, breast cancer, and endometriosis. These conditions are believed to be caused by endocrine-disrupting chemicals such as phthalates, parabens, and formaldehyde-releasing preservatives found in many relaxers.

Research from the National Institutes of Health (NIH) found that women who used hair relaxers frequently were more than twice as likely to develop uterine cancer compared to non-users. Other reported injuries include fibroids, infertility, hormonal imbalance, and early menopause.

These findings have raised serious safety concerns, especially since hair relaxers are often marketed for frequent use without proper warnings about their potential dangers.

Read about the Talcum Powder Lawsuit

Who Can Join the Hair Relaxer Lawsuit and How to File?

Individuals who developed uterine cancer, ovarian cancer, endometriosis, or other hormone-related conditions after long-term use of chemical hair relaxers may qualify to join the hair relaxer lawsuit. The products most commonly cited include those made by L’Oréal, Revlon, SoftSheen-Carson, and Strength of Nature, among others.

To be eligible, plaintiffs should have:

• A confirmed medical diagnosis linked to relaxer use.
• A history of consistent use of chemical relaxers over several years.
• Proof of purchase, product use, or brand identification.

To file, individuals typically contact an attorney handling hair relaxer cancer lawsuits. The attorney will review medical records and usage history and determine eligibility to join the ongoing multidistrict litigation (MDL) currently centralized in the Northern District of Illinois.

Read about the Batiste Dry Shampoo Cancer Lawsuit Updates

Settlement Status and Compensation Outlook in the Hair Relaxer Lawsuit

As of 2025, the hair relaxer lawsuit is still active, with no finalized global settlements yet. The multidistrict litigation (MDL) is proceeding through discovery in the Northern District of Illinois, where thousands of women have filed claims alleging that long-term use of chemical hair relaxers caused serious health problems, including uterine and ovarian cancer.

Settlement talks are expected to begin once early bellwether trials establish how juries respond to the evidence. Based on similar product liability cases, potential compensation could range from $100,000 to over $1 million per plaintiff, depending on the severity of the illness, proof of product use, and medical documentation.

Plaintiffs who suffered from fibroids or endometriosis may receive lower settlements, while those diagnosed with reproductive cancers could see significantly higher payouts. Factors such as brand exposure, frequency of use, and the strength of expert testimony will heavily influence compensation outcomes.

Although the process is ongoing, legal experts anticipate that the first major settlement announcements could occur once key trials conclude and liability is more clearly established.

Read about the OGX Hair Loss Lawsuits

Legal Strategies, Court Decisions & What They Mean for the Hair Relaxer Lawsuit

The hair relaxer lawsuit has evolved into one of the most significant product liability actions in recent years, focusing on allegations that manufacturers such as L’Oréal, Strength of Nature, and others failed to warn consumers about toxic chemicals in their products. Plaintiffs argue these hair relaxers contained endocrine-disrupting ingredients like phthalates and DEHP, which may increase the risk of uterine and ovarian cancers.

Attorneys representing plaintiffs are building their cases on scientific studies, including the 2022 NIH Sister Study, which found that women who regularly used chemical hair straighteners were more than twice as likely to develop uterine cancer compared to non-users. This research has become a cornerstone of the plaintiffs’ legal strategy, emphasizing corporate negligence and failure to test for long-term safety.

Defense teams, on the other hand, are challenging the scientific connection between the products and cancer risk, arguing that correlation does not prove causation. They are also attempting to dismiss claims based on the statute of limitations, product identification issues, and insufficient expert testimony.

In late 2024, the court overseeing the MDL denied several motions from the defense to dismiss the cases, allowing discovery and expert review to continue. This ruling strengthened plaintiffs’ position by confirming that the scientific evidence linking chemical relaxers and reproductive cancers was sufficient to move forward.

These decisions mark a significant turning point in the hair relaxer lawsuit, signaling that future trials could establish a clear precedent on corporate responsibility for cosmetic safety. If plaintiffs succeed in proving negligence or failure to warn, the resulting verdicts could shape how beauty companies disclose ingredient risks in the future.

What Comes Next in the Hair Relaxer Lawsuit?

As the hair relaxer lawsuit moves through 2025, the litigation is expected to enter a critical phase focused on expert testimony, discovery, and potential settlement talks. With over 8,000 federal cases consolidated in multidistrict litigation (MDL No. 3060) before Judge Mary Rowland in the Northern District of Illinois, both sides are preparing for the first bellwether trials, which could begin in late 2025 or early 2026.

These early trials will be essential in shaping how future cases proceed. If juries side with plaintiffs, it could encourage broader settlement discussions with major defendants such as L’Oréal, Strength of Nature, and Revlon. A strong plaintiff verdict may also pressure companies to reformulate their products and include clearer cancer risk warnings on labels.

Discovery efforts will continue to uncover internal corporate communications about what manufacturers knew regarding the potential link between chemical relaxers and reproductive health issues. Expert testimony on toxicology and epidemiology will play a crucial role in proving causation and determining whether exposure to endocrine-disrupting chemicals led to uterine, ovarian, and breast cancers.

While no global settlement has yet been reached, legal analysts anticipate the first compensation framework could emerge after the initial trials. For now, the hair relaxer lawsuit remains one of the most closely watched mass torts in the beauty and product safety industry, with outcomes that could set lasting precedents for cosmetic liability and consumer protection.

Read about the Zantac Lawsuit Updates

Frequently Asked Questions on Hair Relaxer Lawsuit